Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Ashina, Messoud, Saper, Joel, Cady, Roger, Schaeffler, Barbara A, Biondi, David M, Hirman, Joe, Pederson, Susan, Allan, Brent, Smith, Jeff
Published in Cephalalgia (01.03.2020)
Published in Cephalalgia (01.03.2020)
Get full text
Journal Article
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Sun, Hong, MD, Dodick, David W, Prof, Silberstein, Stephen, MD, Goadsby, Peter J, MD, Reuter, Uwe, MD, Ashina, Messoud, Prof, Saper, Joel, MD, Cady, Roger, MD, Chon, Yun, PhD, Dietrich, Julie, MS, Lenz, Robert, Dr
Published in Lancet neurology (01.04.2016)
Published in Lancet neurology (01.04.2016)
Get full text
Journal Article
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
Kudrow, David, Cady, Roger K, Allan, Brent, Pederson, Susan M, Hirman, Joe, Mehta, Lahar R, Schaeffler, Barbara A
Published in BMC neurology (19.03.2021)
Published in BMC neurology (19.03.2021)
Get full text
Journal Article
Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study
Silberstein, Stephen D, Calhoun, Anne H, Lipton, Richard B, Grosberg, Brian M, Cady, Roger K, Dorlas, Stefanie, Simmons, Kristy A, Mullin, Chris, Liebler, Eric J, Goadsby, Peter J, Saper, Joel R
Published in Neurology (02.08.2016)
Published in Neurology (02.08.2016)
Get more information
Journal Article
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
Silberstein, Stephen, Diamond, Merle, Hindiyeh, Nada A., Biondi, David M., Cady, Roger, Hirman, Joe, Allan, Brent, Pederson, Susan, Schaeffler, Barbara, Smith, Jeff
Published in Journal of headache and pain (06.10.2020)
Published in Journal of headache and pain (06.10.2020)
Get full text
Journal Article
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide
Moldovan Loomis, Cristina, Dutzar, Benjamin, Ojala, Ethan W, Hendrix, Lee, Karasek, Charlie, Scalley-Kim, Michelle, Mulligan, Jenny, Fan, Pei, Billgren, Jens, Rubin, Vanessa, Boshaw, Heidi, Kwon, Gayle, Marzolf, Sam, Stewart, Erica, Jurchen, David, Pederson, Susan M, Perrino McCulloch, Lisa, Baker, Brian, Cady, Roger K, Latham, John A, Allison, Dan, Garcia-Martinez, Leon F
Published in The Journal of pharmacology and experimental therapeutics (01.04.2019)
Published in The Journal of pharmacology and experimental therapeutics (01.04.2019)
Get full text
Journal Article
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline
Silberstein, Stephen D, Blumenfeld, Andrew M, Cady, Roger K, Turner, Ira M, Lipton, Richard B, Diener, Hans-Christoph, Aurora, Sheena K, Sirimanne, Mai, DeGryse, Ronald E, Turkel, Catherine C, Dodick, David W
Published in Journal of the neurological sciences (15.08.2013)
Published in Journal of the neurological sciences (15.08.2013)
Get full text
Journal Article
Using artificial intelligence to identify patients with migraine and associated symptoms and conditions within electronic health records
Riskin, Daniel, Cady, Roger, Shroff, Anand, Hindiyeh, Nada A, Smith, Timothy, Kymes, Steven
Published in BMC medical informatics and decision making (14.07.2023)
Published in BMC medical informatics and decision making (14.07.2023)
Get full text
Journal Article
Long-Term Efficacy of a Double-Blind, Placebo-Controlled, Randomized Study for Repetitive Sphenopalatine Blockade With Bupivacaine vs Saline With the Tx360® Device for Treatment of Chronic Migraine
Cady, Roger K., Saper, Joel, Dexter, Kent, Cady, Ryan J., Manley, Heather R.
Published in Headache (01.04.2015)
Published in Headache (01.04.2015)
Get full text
Journal Article
AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
Tepper, Stewart J., Cady, Roger K., Silberstein, Stephen, Messina, John, Mahmoud, Ramy A., Djupesland, Per G., Shin, Paul, Siffert, Joao
Published in Headache (01.05.2015)
Published in Headache (01.05.2015)
Get full text
Journal Article